Pfizer’s combination Covid, flu vaccine will move to final-stage trial after positive data

Pfizer’s combination Covid, flu vaccine will move to final-stage trial after positive data


CFOTO | Future Publishing | Getty Images

Pfizer on Thursday said its combination vaccine candidates targeting Covid and the flu will move to a final-stage trial in the coming months after showing positive initial results in an early to mid-stage study.

That moves the pharmaceutical giant and its German partner BioNTech one step closer to winning a potential regulatory approval for a combination shot for Covid and the flu. Earlier this year, Pfizer said it hopes to launch a vaccine targeting those two respiratory viruses in 2024 or later.

Pfizer and other vaccine makers like Moderna and Novavax believe combination shots will simplify the process for people to protect themselves against respiratory viruses that typically surge around the same time of the year.

“This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices,” Annaliesa Anderson, Pfizer’s head of vaccine research and development, said in a release. 

Pfizer CEO Albert Bourla said during an investor call earlier this month that he believes the convenience offered by combination vaccines will “unlock a significant potential by improving the vaccination rates.” 

Covid vaccine rates in the U.S. were bleak last year, and could look the same this year.

The trial measured the safety, tolerability and efficacy of Pfizer’s combination vaccine candidates among adults ages 18 to 64. The trial also compared the combination vaccines to a licensed influenza vaccine and Pfizer’s bivalent Covid shot, which targets the omicron variants BA.4 and BA.5 and the original strain of the virus. 

The results showed that “lead” formulations of Pfizer’s combination vaccine demonstrated robust immune responses to influenza A, influenza B and Covid strains, according to Pfizer. The safety profiles of the combination vaccine candidates were also consistent with the company’s Covid vaccine.

Pfizer and BioNTech are also developing a vaccine that targets both Covid and RSV. Meanwhile, both Moderna and Novavax are developing their own combination shots.



Source

Supreme Court allows Trump’s cuts to health research grants over DEI policies
Health

Supreme Court allows Trump’s cuts to health research grants over DEI policies

The Supreme Court on Thursday allowed Trump administration broad cuts to National Institutes of Health grants as part of the federal government’s campaign against diversity, equity and inclusion policies. But in a mixed decision the court left in place a different part of the lower court judge’s ruling that threw out the administration’s guidance document that introduced the policy, […]

Read More
Microplastics are everywhere. Here’s why that matters to big oil
Health

Microplastics are everywhere. Here’s why that matters to big oil

Microplastics are increasingly being found in our bodies and food supply.  They are defined as pieces of plastic smaller than 5 millimeters — about the size of a pencil eraser. But they can also be much smaller, like the size of a virus particle or a strand of DNA. Petrochemicals, the building blocks of plastic, […]

Read More
FDA approves first-ever glucose monitoring system for weight loss from Signos 
Health

FDA approves first-ever glucose monitoring system for weight loss from Signos 

Woman with Signos wearable and app Source: Signos The Food and Drug Administration on Wednesday approved the first-ever glucose monitoring system specifically for weight loss from the startup Signos, establishing a new option for Americans to manage their weight.  Current treatment options for losing weight – popular drugs like GLP-1s and surgical interventions – are […]

Read More